1Narod SA,Risch H,Moslehi R,et al.Oral contraceptives and the risk of hereditary ovarian cancer.Hereditary ovarian cancer clinical study group[J].N Engl J Med,1998,339:424-428.
2Narod SA,Sun P,Ghadirian P,et al.Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2mutations:A case-control study[J].Lancet,2001,357:1467-1470.
3Kauff N,Satagopian J,Robson M,et al.Risk reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation[J].N Engl J Med,2002,346:1609-1615.
4Tsao AS,Kim ES,Hong WK.Chemoprevention of cancer[J].CA Cancer J Clin,2004,54:150-180.
5Brewer MA,Johnson K,Follen M,et al.Prevention of ovarian cancer:intraepithelial neoplasia[J].Clin Cancer Res,2003,9:20-30.
6Skates SJ,Horick N,Yu Y,et al.Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125 Ⅱ,CA 15-3,CA 72-4,and macrophage colony-stimulating factor using mixtures of multivariate normal distributions[J].J Clin Oncol,2004,22:4059-4066.
7Parkin DM,Bray F,Ferlay J,et al.Global cancer statistics,2002[J].CA Cancer J Clin,2005,55:74-108.
8Barnes MN,Grizzle WE,Grubbs C J,et al.Paradigms for primary prevention of ovarian carcinoma[J].CA Cancer J Clin,2002,52:216-225.
